Dot blotting method for detecting activity of GSK-3beta proteins of human blood platelets
A platelet and β protein technology, applied in the field of biomedicine, can solve the problem of lack of ideal monitoring methods for GSK-3β protein activity, and achieve the effect of simple operation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0031] Embodiment 1 Establishment of the Dot-blot method of the present invention
[0032] 1. Platelet separation and purification.
[0033] 1.1 Human whole blood 5ml, 60g, centrifuged at 4 degrees Celsius for 15 minutes, the upper layer is plasma, the middle layer is white blood cells, and the lower layer is red blood cells. Plasma, 60g, centrifuged at 4°C for 15min, to remove sediment, centrifuged at 1500g for 15min, divided into 2 layers, the upper layer was serum, and the lower layer was platelets.
[0034] 1.2 Platelet samples were washed with modified Tyrode's solution, centrifuged at 1500g for 5min three times, and stored in a -80°C refrigerator.
[0035] 2. Platelet protein extraction and concentration determination.
[0036] 2.1 Add 120 μl of pre-cooled lysate to platelet 2×Buffer, the 2×Buffer is composed of 50mM Tris-Cl pH 8.0, 1% NP-40, 150mM NaCl, 0.1% SDS, 0.02% NaNR3R, 20% glycerol, cocktail, Composed of 1% PMSF, after standing on ice for 20 minutes, the prot...
Embodiment 2
[0046] Comparison of platelet GSK-3β activity in type 2 diabetes mellitus (T2DM) group and patients with T2DM and MCI detected by dot blot
[0047] 1. Experimental methods: ① Inclusion criteria: Diabetic patients aged >50 years old; no visual and hearing impairments that significantly affect cognitive tests; no history of severe hypoglycemia, diabetic ketosis coma, and hyperosmolar coma; no alcohol dependence and psychoactivity History of substance abuse; no brain trauma, no cardiovascular and cerebrovascular events, including cerebral infarction, cerebral hemorrhage, TIA, myocardial infarction, etc.; no other serious physical diseases that affect cognitive tests, such as epilepsy, hypothyroidism, hypoxemia symptoms, etc.; no history of mental illness; voluntary participation in this study, able to cooperate with the examination, and good compliance. ②Study groups: type 2 diabetes without cognitive impairment T2DM group (T2DM), type 2 diabetes with mild cognitive impairment MC...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com